For: | Mancuso A, Maringhini A. Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect. Am J Surg 2018;216:389-90. [PMID: 28454660 DOI: 10.1016/j.amjsurg.2017.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | López Ortega S, González Grande R, Santaella Leiva I, De la Cruz Lombardo J, Jiménez Pérez M. Efficacy and Safety of Sorafenib After Liver Transplantation: Experience in Our Center. Transplant Proc 2020;52:540-2. [PMID: 32057495 DOI: 10.1016/j.transproceed.2019.12.016] [Reference Citation Analysis] |
2 | Ma Y, Zhang C, Zhang B, Yu H, Yu Q. circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. Oncol Lett 2019;17:388-97. [PMID: 30655779 DOI: 10.3892/ol.2018.9606] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis] |